BIM-23244, a somatostatin receptor subtype 2- and 5- selective analog with enhanced efficacy in suppressing growth hormone (GH) from octreotide-resistant human GH-secreting adenomas

Journal of Clinical Endocrinology and Metabolism

Volumn 86, Issue 1, 2001, Pages 140-145

  Saveanu, A ^a   Gunz, G ^a   Dufour, H ^c   Caron, P ^d   Fina, F ^b   Ouafik, L ^b   Culler, M D ^e   Moreau, J P ^e   Enjalbert, A ^a   Jaquet, P ^a  

^a CNRS   (France)

^b AIX MARSEILLE UNIVERSITY   (France)

^c TIMONE HOSPITAL   (France)

^d Service d'Endocrinologie de Toulouse   (France)

^e Biomeasure Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPEPTIN; BIM 23197; BIM 23244; BIM 23268; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; GROWTH HORMONE; OCTREOTIDE; PROLACTIN; SOMATOMEDIN C; SOMATOSTATIN 14; SOMATOSTATIN DERIVATIVE; UNCLASSIFIED DRUG;

ACROMEGALY; ADENOMA; ADULT; ARTICLE; CLINICAL ARTICLE; DOSE RESPONSE; DRUG EFFICACY; DRUG SENSITIVITY; FEMALE; GROWTH HORMONE RELEASE; HORMONE DETERMINATION; HORMONE INHIBITION; HUMAN; HYPOPHYSIS ADENOMA; MALE; PRIORITY JOURNAL; PROLACTINOMA; TUMOR CELL CULTURE;

ACROMEGALY; ADENOMA; ADULT; DRUG RESISTANCE; FEMALE; HORMONES; HUMAN GROWTH HORMONE; HUMANS; MALE; MIDDLE AGED; OCTREOTIDE; PITUITARY NEOPLASMS; PROLACTIN; RECEPTORS, SOMATOSTATIN; RNA, MESSENGER; SOMATOSTATIN; TUMOR CELLS, CULTURED;

EID: 17744399907     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.86.1.140     Document Type: Article

References (29)

1. Safety and efficacy of long term octreotide therapy of acromegaly: Results of a multicenter trial in 103 patients. A clinical research center study
2. In vivo responsiveness of morphological variants of growth hormone-producing pituitary adenomas to octreotide
3. Long term effect of incremental doses of the somatostatin analog SMS 201-995 in 58 acromegalic patients
4. Specific somatostatin receptors on human pituitary adenoma cell membranes
5. The growth hormone responses to octreotide in acromegaly correlate with adenoma somatostatin receptor status
6. Subtype selectivity of peptide analogs for all five cloned human somatostatin receptors (hsstrl-5)
7. Somatostatin receptor (SSTR) subtype-selective analogs differentially suppress in vitro growth hormone and prolactin in human pituitary adenomas. Novel potential therapy for functional pituitary tumors
8. Human somatostatin receptor subtypes in acromegaly: Distinct patterns of mRNA expression and of GH and PRL suppression identify tumoral phenotypes
9. Somatostatin receptor subtype specificity in human fetal pituitary cultures. Differential role of SSTR2 and SSTR5 for growth hormone, thyroid-stimulating hormone, and prolactin regulation
10. Hormonal regulation of prolactin release by human prolactinoma cells cultured in serum-free conditions
11. Octreotide treatment of acromegaly. A randomized, multicenter study
12. Sandostatin LAR in acromegalic patients: Long-term treatment
13. Three year follow-up of acromegalic patients treated with intramuscular slow-release lanreotide
14. The effect of a new slow-release, long-acting somatostatin analogue, lanreotide, in acromegaly
15. Somatostatin receptors, adenylate cyclase activity, and growth hormone (GH) response to octreotide in GH-secreting adenomas
16. Somatostatin receptor subtype gene expression in human and rodent tumors
17. 5 expression in human pituitary, gastroenteropancreatic and mammary tumors: Comparison of mRNA analysis with receptor autoradiography
18. Heterogeneous expression of two somatostatinreceptor subtypes in pituitary tumors
19. Expression of three somatostatin receptor subtypes in pituitary adenomas: Evidence for preferential SSTR5 expression in the mammosomatotroph lineage
20. Somatostatin receptor subtype gene expression in pituitary adenomas
21. Expression of somatostatin receptor (SSTR) subtypes in pituitary adenomas: Quantitative analysis of SSTR2 mRNA by reverse transcription-polymerase chain reaction
22. Gene transcription of receptors for growth hormone-releasing peptide and somatostatin in human pituitary adenomas
23. Expression of mRNA for all five human somatostatin receptors (hSSTR1-5) in pituitary tumors
24. Expression and localization of somatostatin receptor SSTR1, SSTR2 and SSTR3 messenger RNAs in primary human tumors using in situ hybridization
25. Subtypes of the somatostatin receptor assemble as functional homo- and heterodimers
26. Subtype-selective expression of the five somatostatin receptors (hSSTR1-5) in human pancreatic islet cells
27. Inhibition of human pancreatic islet insulin release by receptor-selective somatostatin analogs directed to somatostatin receptor subtype 5
28. Somatostatin inhibits insulin and glucagon secretion via two receptor subtypes: An in vitro study of pancreatic islets from somatostatin receptor 2 knockout mice